HK1115165A1 - Method of diagnosing and treating cancer using b-catenin splice variants - Google Patents

Method of diagnosing and treating cancer using b-catenin splice variants

Info

Publication number
HK1115165A1
HK1115165A1 HK08104793.3A HK08104793A HK1115165A1 HK 1115165 A1 HK1115165 A1 HK 1115165A1 HK 08104793 A HK08104793 A HK 08104793A HK 1115165 A1 HK1115165 A1 HK 1115165A1
Authority
HK
Hong Kong
Prior art keywords
diagnosing
treating cancer
splice variants
catenin
catenin splice
Prior art date
Application number
HK08104793.3A
Other languages
English (en)
Inventor
Mark J Roth
Konrad Huppi
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of HK1115165A1 publication Critical patent/HK1115165A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
HK08104793.3A 2005-02-10 2008-04-30 Method of diagnosing and treating cancer using b-catenin splice variants HK1115165A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65215405P 2005-02-10 2005-02-10
US66708405P 2005-03-30 2005-03-30
PCT/US2006/005032 WO2006086772A2 (en) 2005-02-10 2006-02-10 DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS

Publications (1)

Publication Number Publication Date
HK1115165A1 true HK1115165A1 (en) 2008-11-21

Family

ID=36793829

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08104793.3A HK1115165A1 (en) 2005-02-10 2008-04-30 Method of diagnosing and treating cancer using b-catenin splice variants

Country Status (8)

Country Link
US (2) US8110352B2 (xx)
EP (1) EP1851340B1 (xx)
JP (1) JP5031587B2 (xx)
AU (1) AU2006213610B2 (xx)
CA (1) CA2596845C (xx)
DK (1) DK1851340T3 (xx)
HK (1) HK1115165A1 (xx)
WO (1) WO2006086772A2 (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110352B2 (en) * 2005-02-10 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health & Human Services Method of diagnosing and treating cancer using B-catenin splice variants
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
WO2009148623A2 (en) 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
NZ628463A (en) * 2009-01-14 2015-12-24 Us Health Ratio based biomarkers and methods for use thereof
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
WO2013154128A1 (ja) * 2012-04-11 2013-10-17 塩野義製薬株式会社 新規動脈硬化症治療用医薬組成物及び動脈硬化症治療薬のスクリーニング方法
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1995013375A1 (en) * 1993-11-10 1995-05-18 The Johns Hopkins University Tumor suppressor waf1
AU6866198A (en) 1997-03-24 1998-10-20 Onyx Pharmaceuticals, Inc. Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
US6066500A (en) * 1999-06-25 2000-05-23 Isis Pharmaceuticals Inc. Antisense modulation of Beta catenin expression
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP1272224A4 (en) * 2000-03-31 2004-09-29 Gene Logic Inc GENE EXPRESSION PROFILES IN ESOPHAGIC TISSUE
JP4771576B2 (ja) * 2000-06-12 2011-09-14 譲治 稲澤 Gasc1遺伝子
US20030064384A1 (en) 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
WO2003051905A2 (en) * 2001-12-13 2003-06-26 Exelixis, Inc. Taojiks as modifiers of the beta-catenin pathway and methods of use
AU2003261101A1 (en) * 2002-06-28 2004-01-19 Hong Kong University Of Science And Technology Plasma or serum marker and process for detection of cancer
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
US8110352B2 (en) * 2005-02-10 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health & Human Services Method of diagnosing and treating cancer using B-catenin splice variants

Also Published As

Publication number Publication date
DK1851340T3 (da) 2013-03-11
EP1851340B1 (en) 2013-01-30
EP1851340A4 (en) 2008-08-20
US20120294929A1 (en) 2012-11-22
EP1851340A2 (en) 2007-11-07
AU2006213610B2 (en) 2012-04-05
CA2596845A1 (en) 2006-08-17
US8110352B2 (en) 2012-02-07
US20090111762A1 (en) 2009-04-30
JP2008535474A (ja) 2008-09-04
CA2596845C (en) 2016-11-08
JP5031587B2 (ja) 2012-09-19
AU2006213610A1 (en) 2006-08-17
WO2006086772A2 (en) 2006-08-17
WO2006086772A3 (en) 2007-05-10
US10000813B2 (en) 2018-06-19

Similar Documents

Publication Publication Date Title
HK1115165A1 (en) Method of diagnosing and treating cancer using b-catenin splice variants
IL179059A0 (en) Method of diagnosing prostate cancer
CR10667A (es) Compositions and methods for diagnosing and treating cancer
EP1774895A4 (en) ENDOSCOPE AND ENDOSCOPE REPAIR METHOD
EP1811844A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
IL190871A0 (en) Methods for prediction and prognosis of cancer and monitoring cancer therapy
EP1945754A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
HK1179275A1 (en) Compositions and methods for diagnosing and treating cancer
EP1776471A4 (en) METHOD FOR MEASURING SUSCEPTIBILITY TO CANCER
IL185396A0 (en) Methods of treating gastrointestinal inflammation
PL2032166T3 (pl) Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2000543A4 (en) METHOD FOR THE MOLECULAR DIAGNOSIS OF PROSTATIC CANCER AND NECESSARY FOR CARRYING OUT SAID METHOD
PT1611890E (pt) Métodos para avaliação e tratamento do cancro
EP2171086A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1859725A4 (en) ENDOSCOPE AND REPAIR METHOD
EP2091551A4 (en) METHOD FOR DIAGNOSING AND TREATING ASTHMA
EP1977247A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
EP1756317A4 (en) METHOD FOR IDENTIFYING THE RISK OF OSTEOARTHRITIS AND TREATMENT THEREOF
ZA200709024B (en) Method of well treatment and construction
EP2099491A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER
EP1773860A4 (en) METHOD FOR IDENTIFYING THE RISK OF TYPE II DIABETES AND TREATING THEREOF
EP1757938A4 (en) METHOD FOR THE INVESTIGATION OF INTERSTITIAL CYSTITIS
IL198425A0 (en) Method of diagnosing and treating glioma
EP1916943A4 (en) SYSTEM AND METHOD FOR EVALUATING COGNITIVE FUNCTION AND MEASURING TREATMENT EFFICIENCY
EP1956134A4 (en) FASCINATING TREATMENT OBJECT AND METHOD FOR FIXING TREATMENT THEREFOR